In the latest trading session, Pfizer (PFE) closed at $23.72, marking a -2.47% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...

HSBC downgraded Pfizer Inc. PFE on Monday, citing that the company’s near-term re-rating prospects have weakened despite its ...

Pfizer's business may be in better shape than investors think.

It could prove to be a case of better later than never for the healthcare giant.

Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn’t be treated with surgery, dealing a setback to the closely watched ...

Pfizer said on Thursday that finance chief Dave Denton will leave ⁠on August 15 to return to the consumer goods industry.

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

Innovent Biologics rose as much as 10%, after entering a strategic global licensing and collaboration agreement with Pfizer to develop oncology medicines.

By Michael Erman June 22 (Reuters) - Pfizer said on Monday that one of the key experimental drugs it picked up in its $43 billion 2023 acquisition of Seagen failed to improve survival when compared to ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...